An adaptive Phase II trial may determine that subject enrolment can stop earlier than a traditional fixed length trial, or a trial with a fixed manually conducted interim. Stopping enrolment early can save considerable trial time and also money in reduced subject enrolment costs.
We have developed a spreadsheet to help you assess the possible impact of the approach on your trial and on your drug development program… Find out more.
There’s a really interesting update on the progress of the I-Spy 2 trial here: http://www.onclive.com/publications/obtn/2013 Based on presentations at the 30th Annual Miami Breast Cancer Conference (MBCC) there’s more than usual about the disease and the treatments involved, but there’s also an update on how the different drugs in the trial are performing.
There has been some great coverage of Michael Krams’ talk that he gave at our Transforming Drug Development Conference http://www.innovationsinclinicaltrials.com/ Mike addressed the problems of developing treatments for Alzheimer’s and proposed some radical initiatives to address them. With a nice write up on Bio-IT World http://www.bio-itworld.com, that has also been picked up by Fiercebiotech http://www.fiercebiotechit.com
It’s not clinical trials, but the power of analytical prediction that has been gloriously demonstrated in the American presidential race http://fivethirtyeight.blogs.nytimes.com Nate Silver, the statistician behind 538, is a rare breed of statistician that knows how to communicate and is not afraid to do it. He not only has the nerve to make (fully statistically qualified) [...]